History
2006
Headquarters are established in Israel.
2012
Development and Establishment of extensive supply network worldwide with
the export of generic drugs to 10 different countries.
2013
Launch of “First-to-Market” antibiotics lines – for including Meropenem
2014
Expansion of the company, specifically with focus on specialty pharma
products and unlicensed drugs.
2015
Expansion to oncology and hematology area with numerous “First–to-Market”
blockbusters for example Pemetrexed and Bortezomib
2017
Establishment of the Balkan region office based in Belgrade.
2018
Registration and “First-to-Market” of numerous ophthalmologic products
including Bimatoprost, Travaprost amongst others.
2019
Market expansion in Balkans, with numerous fillings in Albania, Bosnia,
Montenegro and Macedonia. Numerous first-to-market blockbuster approvals
in Israel and Balkans including Treprostinil, Esomeprazole, Azacytidine,
Tigecycline and Caspofungin. Expansion of the strategical vendors and record
amount of drug submissions.
